wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 20. no 4. December 2015  

 Review articles
The use of omalizumab beyond asthma and urticaria
Karol Kempiński, Marek Niedoszytko

Omalizumab is the first immunomodulator registered for the treatment
of severe allergic asthma and chronic urticaria. The effect of omalizumab
is achieved by IgE blockage and other secondary mechanisms resulting
from this blockage. Due to the frequency of IgE- and Th2-dependent
pathophysiologic reactions, its use might extend far beyond treatment
of allergy.
In this article we summarize the experience of the use of omalizumab in
a number of diseases such as bronchopulmonary aspergillosis, allergic
rhinitis, anaphylaxis, food allergy, atopic dermatitis, nasal polyps, eosinophilic
esophagitis, keratoconjunctivitis and others.

keywords: omalizumab, anty-IgE, Xolair, ANN, AZS, ABPA, anafilaksja, omalizumab, anti-IgE, Xolair, allergic rhinitis, atopic dermatitis, ABPA, anaphylaxis

pages: from 223 to 230

estimated time of download (118 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.